Trials / Active Not Recruiting
Active Not RecruitingNCT06079190
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 367 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK4527226 | GSK4527226 will be administered. |
| OTHER | Placebo | Placebo will be administered. |
Timeline
- Start date
- 2023-10-20
- Primary completion
- 2026-09-30
- Completion
- 2026-11-23
- First posted
- 2023-10-12
- Last updated
- 2025-11-14
Locations
97 sites across 16 countries: United States, Argentina, Australia, Canada, Finland, France, Germany, Italy, Netherlands, Norway, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06079190. Inclusion in this directory is not an endorsement.